Skip Navigation

This Article
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Archer, D. F.
Right arrow Articles by Weber, M. E.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Archer, D. F.
Right arrow Articles by Weber, M. E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 11, No. suppl_2, pp. 24-30, 1996
© 1996 European Society of Human Reproduction and Embryology

Management of irregular uterine bleeding and spotting associated with Norplant®

David F. Archer3, Christine A-Philput1 and Margaret E. Weber2

Department of Obstetrics and Gynecology, Eastern Virginia Medical School 601 Colley Avenue, Norfolk 1 Clinical Investigations and Research Department, Portsmouth Naval Medical Center Portsmouth, VA 2 Medical Affairs, Wyeth-Ayerst Laboratories St David's, PA, USA

Correspondence: 3To whom correspondence should be addressed at the Jones Institute for Reproductive Medicine, 601 Colley Avenue, Norfolk, VA 23507, USA

Norplant®, a systemic contraceptive, has been used extensively thoughout the world. A major problem for consumers utilizing Norplant has been irregular, unpredictable uterine bleeding or spotting. This study seeks to determine whether or not an appropriate treatment could be found that will reduce the incidence of spotting and bleeding. Both a pilot study and an interim report of a multi-center trial utilizing ethinyl estradiol 20 µg for 10 days, versus Ibuprofen 800 mg three times a day for 5 days, versus placebo is reported. Based on the interim analysis of the multi-center trial, there is a reduction hi the mean number of spotting days with one of the three treatments compared to the other two treatments (p = 0.044). There was no difference in the number of bleeding days between treatment regimen.

It appears from a review of the literature that both oestrogen, progesterone, and non-steriodal anti-inflammatory agents may reduce the number of bleeding days or inhibit acutely the bleeding in women utilizing NorplanL The completion of this randomized multi-center trial will hopefully give us further insight into an effective treatment for controlling the irregular bleeding and/or spotting that occurs hi Norplant users.

Key words: ethinyl oestradiol/ibuprofen/Norplant/uterine bleeding


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 ReproductionHome page
N. B Morison, T. J Kaitu'u-Lino, I. S Fraser, and L. A Salamonsen
Stimulation of epithelial repair is a likely mechanism for the action of mifepristone in reducing duration of bleeding in users of progestogen-only contraceptives
Reproduction, August 1, 2008; 136(2): 267 - 274.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.